Our Studies
At our core, we stand against pseudoscience. AMINO 9 is built from actives with published, peer-reviewed human evidence — and we are explicit about where that evidence ends. The formulation itself has not yet been through its own randomised trial; a CYBORG cohort study alongside GLP-1 therapy is in design, and we will publish it whichever way it reads.
Clinical evidence
Human trials of the constituent actives — essential amino acids, Ca-HMB and creatine — assessing safety, efficacy and dosing.
Mechanistic & pre-clinical
Laboratory work establishing how the actives behave before human dosing.
A note on these tables. The findings above describe the published evidence base for AMINO 9's individual actives, not trials of the finished product. Specific citations, journals and dates are placeholders for the CYBORG science team to complete before launch — we would rather ship an empty citation slot than a decorative one.
Built on publishedactives, measured on realmembers
Every AMINO 9 member has a baseline and a twelve-week retest.That's not marketing infrastructure — it's how a nutrition claimearns the right to keep being made.
How we decode your data
Decode Human Performance™
† These statements have not been evaluated by the FDA or FSSAI. This product is not intended to diagnose, treat, cure or prevent any disease.
References: *Nutrition studies: the constituent actives of AMINO 9 — essential amino acids with 3.9 g leucine, 3 g Ca-HMB and 1 g creatine HCl — have been studied in randomised human trials. Lean mass and grip strength: Li N, Chen S, He Y, et al. Effects of oral supplementation of β-hydroxy-β-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis. Front Nutr. 2025;12:1522287 — a pooled analysis of 21 randomised trials in 1,935 adults aged over 50, reporting +0.28 kg lean mass (95% CI 0.16–0.41) and +0.54 kg handgrip strength (95% CI 0.04–1.04) against control, at 3 g of Ca-HMB a day for more than 12 weeks. Body fat: Forbes SC, Candow DG, Krentz JR, et al. Changes in fat mass following creatine supplementation and resistance training in adults ≥50 years of age: a meta-analysis. J Funct Morphol Kinesiol. 2019;4(3):62 — a pooled analysis of 19 randomised trials in 609 adults aged over 50, reporting a 0.55 percentage-point fall in body fat (95% CI −1.08 to −0.03) against control; absolute fat mass in the same analysis fell 0.50 kg, which did not reach significance. Those trials used 3–5 g of creatine monohydrate a day, several with a loading week, against the 1 g of creatine HCl in this product. Figures are reported from trials of the individual actives, not of the finished product; no trial of the finished formulation has been completed, the pooled populations are older than the general customer, and the creatine dose studied is higher than the dose supplied. **Free-form amino acids require no proteolytic digestion and reach plasma faster than intact dietary protein: Weijzen MEG, van Gassel RJJ, Kouw IWK, et al. J Nutr. 2022;152(1):59–67, in which free amino acids roughly doubled the peak rate of appearance of exogenous phenylalanine against an equal dose of intact milk protein (0.75 vs 0.38 μmol·kg⁻¹·min⁻¹).
Our Studies
At our core, we stand against pseudoscience. AMINO 9 is built from actives with published, peer-reviewed human evidence — and we are explicit about where that evidence ends. The formulation itself has not yet been through its own randomised trial; a CYBORG cohort study alongside GLP-1 therapy is in design, and we will publish it whichever way it reads.
Clinical evidence
Human trials of the constituent actives — essential amino acids, Ca-HMB and creatine — assessing safety, efficacy and dosing.
EAA
Essential amino acids stimulate muscle protein synthesis independently of total energy intake
Citation pending
Leucine
A per-serving leucine threshold governs whether the synthesis response fires at all
Citation pending
Ca-HMB
HMB attenuates muscle protein breakdown during caloric restriction and disuse
Citation pending
Creatine
Creatine supplementation increases strength and training capacity with resistance exercise
Citation pending
GLP-1
A substantial share of weight lost on incretin therapy is lean tissue when nutrition and training are unsupported
Citation pending
Ongoing
CYBORG 12-week cohort: AMINO 9 alongside clinician-guided GLP-1 therapy
Not yet published
Mechanistic & pre-clinical
Laboratory work establishing how the actives behave before human dosing.
mTOR
Leucine-sensing upstream of mTORC1 as the molecular trigger for translation initiation
Citation pending
Proteolysis
HMB and the ubiquitin-proteasome pathway in models of muscle wasting
Citation pending
Absorption
Free-form amino-acid transport kinetics versus intact protein hydrolysis
Citation pending
A note on these tables. The findings above describe the published evidence base for AMINO 9's individual actives, not trials of the finished product. Specific citations, journals and dates are placeholders for the CYBORG science team to complete before launch — we would rather ship an empty citation slot than a decorative one.
Built on published actives, measured on real members
Every AMINO 9 member has a baseline and a twelve-week retest. That's not marketing infrastructure — it's how a nutrition claim earns the right to keep being made.
How we decode your dataDecode Human Performance™
SCIENCE
SUPPORT
- HELP CENTER
- CARE@CYBORG.MEN
- +91 88 6313 3359
- REWARDS
NEWSLETTER
† These statements have not been evaluated by the FDA or FSSAI. This product is not intended to diagnose, treat, cure or prevent any disease.
References: *Nutrition studies: the constituent actives of AMINO 9 — essential amino acids with 3.9 g leucine, 3 g Ca-HMB and 1 g creatine HCl — have been studied in randomised human trials. Lean mass and grip strength: Li N, Chen S, He Y, et al. Effects of oral supplementation of β-hydroxy-β-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis. Front Nutr. 2025;12:1522287 — a pooled analysis of 21 randomised trials in 1,935 adults aged over 50, reporting +0.28 kg lean mass (95% CI 0.16–0.41) and +0.54 kg handgrip strength (95% CI 0.04–1.04) against control, at 3 g of Ca-HMB a day for more than 12 weeks. Body fat: Forbes SC, Candow DG, Krentz JR, et al. Changes in fat mass following creatine supplementation and resistance training in adults ≥50 years of age: a meta-analysis. J Funct Morphol Kinesiol. 2019;4(3):62 — a pooled analysis of 19 randomised trials in 609 adults aged over 50, reporting a 0.55 percentage-point fall in body fat (95% CI −1.08 to −0.03) against control; absolute fat mass in the same analysis fell 0.50 kg, which did not reach significance. Those trials used 3–5 g of creatine monohydrate a day, several with a loading week, against the 1 g of creatine HCl in this product. Figures are reported from trials of the individual actives, not of the finished product; no trial of the finished formulation has been completed, the pooled populations are older than the general customer, and the creatine dose studied is higher than the dose supplied. **Free-form amino acids require no proteolytic digestion and reach plasma faster than intact dietary protein: Weijzen MEG, van Gassel RJJ, Kouw IWK, et al. J Nutr. 2022;152(1):59–67, in which free amino acids roughly doubled the peak rate of appearance of exogenous phenylalanine against an equal dose of intact milk protein (0.75 vs 0.38 μmol·kg⁻¹·min⁻¹).